Core Insights - Onco-Innovations Limited has announced a collaboration with Nucro-Technics Inc. to conduct preclinical and analytical development services [1] - The initial phase of the project focuses on developing and validating advanced analytical methods for measuring Onco's Polynucleotide Kinase Phosphatase (PNKP) inhibitor [1] Company Developments - Nucro-Technics, a Toronto-based contract research organization, has begun laboratory work under Onco's Investigational New Drug (IND) enabling program [1] - The collaboration aims to enhance the analytical capabilities related to Onco's exclusively licensed technology [1]

Group 1 - Onco-Innovations Limited has announced that Dalton Pharma Services has started manufacturing its proprietary nanoparticle formulation, PEO-b-PBz-CL, which is essential for the company's drug delivery platform [1] - The nanoparticle formulation is intended to be used in conjunction with Onco's proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor [1] - The manufacturing initiative aims to produce the nanoparticle material necessary to advance preclinical studies [1]